Table 3.
Occurrence of non-infectious and infectious AE
| TNFi treatment number of events | No TNFi treatment number of events | Relative risk (95% CI) | |
|---|---|---|---|
| Infections | |||
| Upper respiratory tract infection | 46 | 13 | 1.51 (0.91, 2.50) |
| Herpes simplex | 4 | 1 | 1.71 (0.20, 14.86) |
| Acute infectious diarrhea | 2 | 5 | 0.17 (0.03, 0.85)* |
| Urinary tract infection | 1 | 0 | 1.30 (0.05, 31.26) |
| Lower respiratory tract infection | 1 | 0 | 1.30 (0.05, 31.26) |
| Genital tract infection | 1 | 0 | 1.30 (0.05, 31.26) |
| Skin Infection | 1 | 0 | 1.30 (0.05, 31.26) |
| Otitis media | 1 | 0 | 1.30 (0.05, 31.26) |
| Non-infectious AE | |||
| Abdominal pain | 4 | 9 | 0.20 (0.07, 0.63)** |
| Elevated transaminases | 3 | 3 | 0.46 (0.10, 2.17) |
| Leukopenia | 3 | 2 | 0.68 (0.12, 3.91) |
| Skin changes | 0 | 3 | 0.07 (0.004, 1.25) |
| Diarrhea | 0 | 2 | 0.09 (0.005, 1.89) |
| Uveitis | 2 | 1 | 0.91 (0.08, 9.82) |
| Psoriasis | 1 | 0 | 1.39 (0.06, 33.37) |
| Nausea | 1 | 0 | 1.39 (0.06, 33.37) |
| Dizziness | 1 | 0 | 1.39 (0.06, 33.37) |
| Tachycardia | 1 | 0 | 1.39 (0.06, 33.37) |
| Periodontitis | 1 | 0 | 1.39 (0.06, 33.37) |
| Colitis | 0 | 1 | 0.15 (0.006, 3.71) |
AE adverse events, TNFi TNF inhibitors
*p = 0.0306, **p = 0.0055